Objectives The prevalence and clinical outcomes of COVID-19 in patients with autoimmune
diseases who are frequently treated with disease modifying therapies remains poorly …

Abstract The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused significant morbidity and …

Objectives To determine factors associated with COVID-19-related death in people with
rheumatic diseases. Methods Physician-reported registry of adults with rheumatic disease …

Though the exact etiology of autoimmune diseases still remains unknown, there are various
factors which are believed to contribute to the emergence of an autoimmune disease in a …

Objectives COVID-19 outcomes in people with rheumatic diseases remain poorly
understood. The aim was to examine demographic and clinical factors associated with …

Objective To investigate baseline use of biologic or targeted synthetic (b/ts) disease-
modifying antirheumatic drugs (DMARDs) and COVID-19 outcomes in rheumatoid arthritis …

Importance Risk factors associated with the severity of coronavirus disease 2019 (COVID-
19) in patients with multiple sclerosis (MS) are unknown. Disease-modifying therapies …

Aims To estimate the prevalence of established diabetes and its association with the clinical
severity and in-hospital mortality associated with COVID-19. Data synthesis We …

Abstract Aim Coronavirus disease 2019 (COVID-19) is a novel highly contagious infection
caused by SARS-CoV-2, which has been became a global public health challenge. The …

Objective To investigate differences in manifestations and outcomes of coronavirus disease
2019 (COVID-19) infection between those with and without rheumatic disease. Methods We …